6 research outputs found
Primjena traneksamiÄne kiseline u dermatologiji
Tranexamic acid is a synthetic derivative of the amino acid lysine, an antifibrinolytic
that is primarily used to reduce bleeding in surgery, trauma, and dental procedures. Its anti-inflammatory
and anti-angiogenic properties, as well as its ability to suppress melanogenesis have enabled it to be used
in dermatology in the treatment of skin conditions such as melasma, acne, post-inflammatory hyperpigmentation,
rosacea and angioedema. Tranexamic acid can be used by various routes of administration
including oral, topical and intradermal injection, and in combination with other treatment methods. This
review article presents evidence for the effectiveness of tranexamic acid in the treatment of various skin
disorders.TraneksamiÄna kiselina sintetski je derivat aminokiseline lizina, antifibrinolitika koji se prvenstveno rabi za smanjenje
krvarenja u kirurŔkim zahvatima, traumi i stomatoloŔkim zahvatima. Njegova protuupalna i antiangiogena svojstva, kao i
njegova sposobnost suzbijanja melanogeneze omoguÄili su mu upotrebu u dermatologiji u lijeÄenju kožnih stanja kao Å”to su
melazma, akne, poslijeupalna hiperpigmentacija, rozacea i angioedem. TraneksamiÄnu kiselinu moguÄe je primijeniti na razliÄite
naÄine: oralno, lokalno i intradermalno te u kombinaciji s drugim metodama lijeÄenja. Ovaj pregledni Älanak prikazuje
dokaze o uÄinkovitosti traneksamiÄne kiseline u lijeÄenju razliÄitih kožnih poremeÄaja
Idiopatski asinkroni obostrani segmentalni infarkt testisa - prikaz sluÄaja
We present an unusual case of sudden onset of pain in the left testis in a patient
with a previous medical history of right orchiectomy due to hemorrhagic infarction. A partial orchiectomy
was performed with complete removal of the lesion and reconstruction of the testicular parenchyma.
Histopathological assessment confirmed segmental testicular infarction without the presence
of malignancy. The patient subsequently received anticoagulant therapy.Prikazujemo neobiÄan sluÄaj iznenadne pojave boli u lijevom testisu kod bolesnika u kojeg je prethodno uÄinjena
desnostrana orhidektomija zbog hemoragijskog infarkta. IzvrÅ”ena je djelomiÄna orhidektomija s potpunim uklanjanjem lezije
i rekonstrukcijom parenhima testisa. HistopatoloÅ”kom obradom potvrÄen je segmentalni infarkt testisa bez prisutnosti zloÄudne
bolesti. U bolesnika je nakon toga primjenjena protuzgruÅ”avajuÄa terapija
UÄinak botulinum toksina tip A u bolesnika s esencijalnim blefarospazmom
The aim of this study was to determine the effect of botulinum toxin type A and
satisfaction in patients with essential blepharospasm. The study included 12 subjects suffering from
essential blepharospasm who received therapy with botulinum toxin type A injections. Respondents
were given a Blepharospasm Disability Index (BSDI) survey before and three weeks after the procedure
with questions related to quality of life. They were also given a Jankovic Rating Scale with questions
related to the severity and frequency of symptoms. The overall level of difficulties was reduced, meaning
the quality of life increased after the application of botulinum toxin, and the study found that
the increase was statistically significant (p = 0.003). The severity of symptoms after the application of
botulinum toxin was reduced, which meant that there was a decrease in the severity of the difficulties,
and the study found a statistically significant difference (p=0.003). The frequency of symptoms was
reduced after botulinum toxin administration, and the study revealed a statistically significant difference
(p = 0.012). From the results of this study, we can determine that the use of botulinum toxin
type A increases the quality of life and that the severity and frequency of symptoms are statistically
significantly reduced.Cilj je bio utvrditi uÄinak botulinum toksina tip A i zadovoljstvo u bolesnika s esencijalnim blefarospazmom. U istraživanje
je ukljuÄeno 12 ispitanika u dobi od 49 do 86 godina s esencijalnim blefarospazmom kojima je primijenjena terapija
injekcijama botulinum toksina tip A. Ispitanicima je prije te tri tjedna nakon postupka dana anketa Blepharospasm Disability
Index (BSDI) u kojoj su bila pitanja vezana za kvalitetu života. Dana im je i ljestvica Jankovic Rating Scale s pitanjima koja
se odnose na težinu i uÄestalost simptoma. Ukupna razina poteÅ”koÄa je smanjena, Å”to znaÄi da se kvaliteta života poveÄala
nakon primjene botulinum toksina, a studija je pokazala da je poveÄanje statistiÄki znaÄajno (p = 0,003). Ozbiljnost simptoma
nakon primjene botulinum toksina smanjena je, Å”to znaÄi da je doÅ”lo do smanjenja težine poteÅ”koÄa, a istraživanje je
utvrdilo statistiÄki znaÄajnu razliku (p=0,003). UÄestalost simptoma smanjena je nakon primjene botulinum toksina, a studija
je pokazala statistiÄki znaÄajnu razliku (p = 0,012). Iz rezultata ovog istraživanja možemo utvrditi da primjenom botulinum
toksina tipa A dolazi do poveÄanja kvalitete života, te da se ozbiljnost i uÄestalost simptoma statistiÄki znaÄajno smanjuju
CAN A REDUCED DOSE OF CYTARABINE BE AS EFFECTIVE AS FULL DOSE IN THE TREATMENT OF PRIMARY DIFFUSE B-CELL LYMPHOMA IN MATRix PROTOCOL?
Primarni limfom srediÅ”njeg živÄanog sustava rijetki je agresivan non-Hodgkinov limfom. Suvremeni pristup lijeÄenju
bolesnika podobnih za intenzivnu imuno-kemoterapiju ukljuÄuje faze indukcije i konsolidacije. IELSG32, randomizirano ispitivanje MeÄunarodne grupe za istraživanje ekstranodalnih limfoma (engl. International Extranodal Lymphoma Study Group) pokazalo je kako u indukcijskoj fazi kombinacija visokih doza metotreksata, citarabina, tiotepe i rituksimaba praÄena konsolidacijom autolognom transplantacijom krvotvornih matiÄnih stanica znatno poboljÅ”ava ishode tih bolesnika. Retrospektivno je analizirano sedmero bolesnika s novo dijagnosticiranim primarnim limfomom mozga lijeÄenih od listopada 2018. do veljaÄe 2022. godine koji su primili MATRix protokol kemoterapije s reduciranom dozom citarabina. Primijenjena doza iznosila je 2000 mg/m2 svakih 12 sati treÄeg dana ciklusa. Äetvrtog dana ciklusa citarabin je izostavljen kod svih bolesnika. Pet bolesnika postiglo je kompletnu remisiju, a jedan parcijalnu remisiju. Kod veÄine bolesnika na indukcijsku fazu nastavljena je konsolidacija transplantacijom krvotvornih matiÄnih stanica. Kod jednog bolesnika zabilježena je progresija bolesti tri mjeseca nakon autologne transplantacije krvotvornim matiÄnim stanicama. Terapijske nuspojave su usporedive i sliÄne s rezultatima IELSG32, s naglaskom da su se hematoloÅ”ke toksiÄnosti gradusa 4 javljale u malim brojevima. S obzirom na prikazane kliniÄke sluÄajeve postavlja se pitanje bi li niža doza citarabina u MATRix protokolu mogla biti jednako uÄinkovita kao i puna doza u postizanju remisije bolesti primarnog B-velikostaniÄnog limfoma mozga.Primary diffuse B-cell brain lymphoma is a rare, aggressive non-Hodgkinās lymphoma. The modern approach to treatment involves two phases, induction and consolidation. IELSG32, a randomized trial by the International Extranodal Lymphoma Study Group, showed that in the induction phase, the combination of high doses of methotrexate, cytarabine, thiotepa, and rituximab followed by consolidation therapy with autologous hematopoietic stem cell transplantation signifi cantly improved outcomes in these patients. We aim here to present characteristics and outcomes of seven patients with newly diagnosed primary central nervous system lymphoma who were treated between November 2018 and February 2022. All of them received the MATRix reduced-dose cytarabine chemotherapy protocol. The dose of cytarabine was 2000 mg/ m2 every 12 hours on the third day of the cycle. On the fourth day of the cycle, cytarabine was completely omitted in all patients. Five patients achieved complete remission and one patient achieved partial remission after completion of the induction therapy at a reduced dose, followed by autologous hematopoietic stem cell transplantation in most patients. One patient had progression of the disease three months after autologous hematopoietic stem cell transplantation. Therapeutic toxicities were similar to IELSG32 results with emphasis on the fact that hematologic toxicities of grade 4 occurred in a low percentage. The above raises a question whether a reduced dose of cytarabine in MATRix protocol be as effective as full dose in achieving disease remission
CAN A REDUCED DOSE OF CYTARABINE BE AS EFFECTIVE AS FULL DOSE IN THE TREATMENT OF PRIMARY DIFFUSE B-CELL LYMPHOMA IN MATRix PROTOCOL?
Primarni limfom srediÅ”njeg živÄanog sustava rijetki je agresivan non-Hodgkinov limfom. Suvremeni pristup lijeÄenju
bolesnika podobnih za intenzivnu imuno-kemoterapiju ukljuÄuje faze indukcije i konsolidacije. IELSG32, randomizirano ispitivanje MeÄunarodne grupe za istraživanje ekstranodalnih limfoma (engl. International Extranodal Lymphoma Study Group) pokazalo je kako u indukcijskoj fazi kombinacija visokih doza metotreksata, citarabina, tiotepe i rituksimaba praÄena konsolidacijom autolognom transplantacijom krvotvornih matiÄnih stanica znatno poboljÅ”ava ishode tih bolesnika. Retrospektivno je analizirano sedmero bolesnika s novo dijagnosticiranim primarnim limfomom mozga lijeÄenih od listopada 2018. do veljaÄe 2022. godine koji su primili MATRix protokol kemoterapije s reduciranom dozom citarabina. Primijenjena doza iznosila je 2000 mg/m2 svakih 12 sati treÄeg dana ciklusa. Äetvrtog dana ciklusa citarabin je izostavljen kod svih bolesnika. Pet bolesnika postiglo je kompletnu remisiju, a jedan parcijalnu remisiju. Kod veÄine bolesnika na indukcijsku fazu nastavljena je konsolidacija transplantacijom krvotvornih matiÄnih stanica. Kod jednog bolesnika zabilježena je progresija bolesti tri mjeseca nakon autologne transplantacije krvotvornim matiÄnim stanicama. Terapijske nuspojave su usporedive i sliÄne s rezultatima IELSG32, s naglaskom da su se hematoloÅ”ke toksiÄnosti gradusa 4 javljale u malim brojevima. S obzirom na prikazane kliniÄke sluÄajeve postavlja se pitanje bi li niža doza citarabina u MATRix protokolu mogla biti jednako uÄinkovita kao i puna doza u postizanju remisije bolesti primarnog B-velikostaniÄnog limfoma mozga.Primary diffuse B-cell brain lymphoma is a rare, aggressive non-Hodgkinās lymphoma. The modern approach to treatment involves two phases, induction and consolidation. IELSG32, a randomized trial by the International Extranodal Lymphoma Study Group, showed that in the induction phase, the combination of high doses of methotrexate, cytarabine, thiotepa, and rituximab followed by consolidation therapy with autologous hematopoietic stem cell transplantation signifi cantly improved outcomes in these patients. We aim here to present characteristics and outcomes of seven patients with newly diagnosed primary central nervous system lymphoma who were treated between November 2018 and February 2022. All of them received the MATRix reduced-dose cytarabine chemotherapy protocol. The dose of cytarabine was 2000 mg/ m2 every 12 hours on the third day of the cycle. On the fourth day of the cycle, cytarabine was completely omitted in all patients. Five patients achieved complete remission and one patient achieved partial remission after completion of the induction therapy at a reduced dose, followed by autologous hematopoietic stem cell transplantation in most patients. One patient had progression of the disease three months after autologous hematopoietic stem cell transplantation. Therapeutic toxicities were similar to IELSG32 results with emphasis on the fact that hematologic toxicities of grade 4 occurred in a low percentage. The above raises a question whether a reduced dose of cytarabine in MATRix protocol be as effective as full dose in achieving disease remission
THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM
Cilj istraživanja: Cilj ovog istraživanja bio je utvrditi uÄinak botulinum toksina tipa A i zadovoljstvo kod pacijenata s esencijalnim blefarospazmom.
Ispitanici i metode: U ovo prospektivno eksperimentalno istraživanje ukljuÄeno je 12 ispitanika koji boluju od esencijalnog blefarospazma te im je primijenjena terapija injekcijama botulinum toksina tipa-A. Istraživanje se provodilo u Klinici za oÄne bolesti KliniÄkog bolniÄkog centra Split u razdoblju od prosinca 2019. do lipnja 2021. godine. U studiju je ukljuÄeno 11 žena i 1 muÅ”karac u dobi od 49 do 86 godina. Ispitanicima je prije te dva do tri tjedna nakon zahvata dana anketa u kojoj se pitanja odnose na kvalitetu života i ukljuÄuju poteÅ”koÄe pri Äitanju, vožnji, gledanju televizije, izvoÄenju svakodnevnih aktivnosti, Å”etanju i kupovini u duÄanu. TakoÄer im je dana ljestvica āJankovic Rating Scaleā u kojoj se pitanja odnose na ozbiljnost i uÄestalost simptoma. U terapiji se koristio botulinum toksin tipa- A (Botox) koji smo razrijedili s 4 ml fizioloÅ”ke otopine, tako da je u inzulinskoj brizgalici s integriranom iglom, od jednog mililitra 25 jedinica lijeka. Svi pacijenti su dobili po 25 jedinica po strani, u pet toÄaka (5 jedinica po toÄki) subkutano i to na dva mjesta na gornjoj vjeÄi, zatim u srediÅ”njem podruÄju m. orbicularis oculi na donjoj vjeÄi te u dvije toÄke u lateralnom dijelu miÅ”iÄa.
Rezultati: Ukupna razina poteÅ”koÄa snižena je (3,0 (2,2-3,2) vs. 1,6 (0,6-1,8)), odnosno kvaliteta života je narasla nakon primjene botulinum toksina, te je ispitivanjem utvrÄeno da je porast statistiÄki znaÄajan (P=0,003). Ozbiljnost simptoma nakon primjene botulinum toksina snižena je (3,5 (3,0-4,0) vs. 2,0(1,0-2,0), Å”to znaÄi da je doÅ”lo do smanjenja ozbiljnosti poteÅ”koÄa, te je ispitivanjem utvrÄeno postojanje statistiÄki znaÄajne razlike (P=0,003). UÄestalost simptoma je nakon primjene botulinum toksina snižena (3,0 (3,0-3,0) vs. 1,0 (1,0-2,5)), te je ispitivanjem utvrÄeno postojanje statistiÄki znaÄajne razlike (P=0,012).
ZakljuÄak: Iz rezultata ovog istraživanja možemo utvrditi da primjenom botulinum toksina tipa-A dolazi do poveÄanja kvalitete života, te da se ozbiljnost i uÄestalost simptoma statistiÄki znaÄajno smanjuju.Objectives: The aim of this study was to determine the effect of botulinum toxin type A and satisfaction in patients with essential blepharospasm.
Subjects and methods: This prospective experimental study included 12 subjects suffering from essential blepharospasm who received therapy with botulinum toxin type-A injections. The research was conducted at the Department of Ophthalmology of University Medical Center Split between December 2019 and June 2021. The study included 11 women and 1 man aged 49 to 86 years. Respondents were given a survey before and two to three weeks after the procedure in which were questions related to quality of life including difficulties in reading, driving, watching television, doing everyday activities, walking and shopping in the store. They were also given a "Jankovic Rating Scale" with questions related to the severity and frequency of symptoms. Botulinum toxin type-A (Botox) was used in the therapy and was diluted with 4 ml of physiological solution, so that in an insulin syringe with an integrated needle, there are 25 units of the drug from one milliliter. All patients received 25 units per side, at five points (5 units per point) subcutaneously in two places on the upper eyelid, then in the central area of the m. orbicularis oculi on the lower eyelid and at two points in the lateral part of the muscle.
Results: The overall level of difficulties was reduced (3,0 (2,2-3,2) vs. 1,6 (0,6-1,8)), meaning the quality of life increased after the application of botulinum toxin, and the study found that the increase was statistically significant (P = 0.003). The severity of symptoms after the application of botulinum toxin was reduced (3,5 (3,0-4,0) vs. 2,0(1,0-2,0), which means that there was a decrease in the severity of the difficulties, and the study found a statistically significant difference (P=0,003). The frequency of symptoms was reduced after botulinum toxin administration (3,0 (3,0-3,0) vs. 1,0 (1,0-2,5)), and the study revealed a statistically significant difference (P = 0.012).
Conclusions: From the results of this study, we can determine that the use of botulinum toxin type-A increases the quality of life, and that the severity and frequency of symptoms are statistically significantly reduced